Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of March 2015, with the report dated March 13, 2015. The registrant is a foreign private issuer based in Tel Aviv, Israel, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a specific corporate agreement rather than a financial results statement.
Material Changes
The primary material event disclosed is the attachment of a Master Service Agreement dated July 5, 2011, between 7810962 Canada Inc. and Redhill Biopharma Ltd. regarding the compound RHB-105. Portions of this exhibit were omitted and filed separately under a confidential treatment request.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, or a discussion of risks and contingencies. The document focuses solely on incorporating the referenced Master Service Agreement into the company's existing Registration Statements on Form S-8 and Form F-3.
Key Facts for Investor Verification
- Verify the terms and status of the Master Service Agreement regarding RHB-105 with 7810962 Canada Inc.
- Confirm the details of the confidential treatment request filed separately with the SEC for portions of the agreement.
- Note that this filing does not contain updated financial performance data for the period.